Antibody‐mediated rejection despite inhibition of terminal complement

Terminal complement blockade has been shown to decrease the incidence of early acute antibody‐mediated rejection (eAMR) in the first month after positive cross‐match kidney transplant recipients, yet some patients still develop eAMR. The current study investigated possible mechanisms of eAMR despite eculizumab treatment. Of the 26 patients treated with eculizumab, two developed clinical eAMR and another patient developed histologic signs of eAMR without graft dysfunction (‘subclinical eAMR’). Twenty‐three did not have histologic injury on early surveillance biopsies. All 26 patients had therapeutic levels of eculizumab and showed complete blockade of complement in hemolytic assays. High levels of donor‐specific alloantibody (DSA) including total IgG, IgG3, and C1q+ DSA were present in patients with and without eAMR, and none correlated well with eAMR. In contrast, IgM DSA was present in only four patients after transplantation: the two patients with clinical eAMR, one patient with subclinical AMR, and one patient without eAMR (P = 0.006 correlation with eAMR). Both clinical eAMR episodes were easily treated with plasma exchange which removed IgM more completely and rapidly than IgG, resulting in normalization of function and histology. These data suggest a possible role of antidonor IgM DSA in the pathogenesis of eAMR in patients treated with terminal complement blockade (ClinicalTrials.gov Identifier: NCT00670774).

[1]  C. Haisch,et al.  Impact of IgM and IgG3 Anti-HLA Alloantibodies in Primary Renal Allograft Recipients , 2014, Transplantation.

[2]  M. Stegall,et al.  The role of complement in antibody-mediated rejection in kidney transplantation , 2012, Nature Reviews Nephrology.

[3]  G. Klintmalm,et al.  Donor‐specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  M. Stegall,et al.  Terminal Complement Inhibition Decreases Antibody‐Mediated Rejection in Sensitized Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  D. Tyan,et al.  Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. , 2011, Human immunology.

[6]  D. Tyan,et al.  14-OR Parallel C1q and IgG assays on single antigen beads reveal that the presence of IgM complement fixing antibodies can obscure clinically relevant IgG antibodies to the same allele , 2011 .

[7]  B. Lavingia,et al.  Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. , 2009, Human immunology.

[8]  M. Stegall,et al.  Mechanisms of Alloantibody Production in Sensitized Renal Allograft Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  M. Stegall,et al.  Alloantibody Levels and Acute Humoral Rejection Early After Positive Crossmatch Kidney Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  E. Reed,et al.  HLA Class I Antibody-Mediated Endothelial Cell Proliferation via the mTOR Pathway1 , 2008, The Journal of Immunology.

[11]  W. Baldwin,et al.  Antibody and complement in transplant vasculopathy. , 2007, Circulation research.

[12]  M. Müllner,et al.  Immunoadsorption in Severe C4d‐Positive Acute Kidney Allograft Rejection: A Randomized Controlled Trial , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  J. Buras,et al.  Mannose binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo , 2006, Immunobiology.

[14]  M. Stegall,et al.  A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  D. Mancini,et al.  Immunoglobulin M-to-Immunoglobulin G Anti-Human Leukocyte Antigen Class II Antibody Switching in Cardiac Transplant Recipients Is Associated With an Increased Risk of Cellular Rejection and Coronary Artery Disease , 2005, Circulation.

[16]  P. Terasaki,et al.  Serial Ten‐Year Follow‐Up of HLA and MICA Antibody Production Prior to Kidney Graft Failure , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  Rodney K. Chan,et al.  IgM binding to injured tissue precedes complement activation during skeletal muscle ischemia-reperfusion. , 2004, The Journal of surgical research.

[18]  I. Doxiadis,et al.  Detection and specification of noncomplement binding anti-HLA alloantibodies. , 2004, Human immunology.

[19]  Zu-hua Gao,et al.  Protective anti‐donor IgM production after crossmatch positive liver–kidney transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  T. Larson,et al.  Overcoming a Positive Crossmatch in Living‐Donor Kidney Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  Susan Martin,et al.  The detection and definition of IgM alloantibodies in the presence of IgM autoantibodies using flowPRA beads. , 2003, Human immunology.

[22]  S. Sacks,et al.  Local synthesis of complement component C3 regulates acute renal transplant rejection , 2002, Nature Medicine.

[23]  C. Bryan,et al.  IgM antibodies identified by a DTT‐ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype* , 2001, Clinical transplantation.

[24]  S. Gruber,et al.  Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. , 1999, Transplantation.

[25]  S. Galli,et al.  Impaired mast cell-dependent natural immunity in complement C3-deficient mice , 1997, Nature.

[26]  L. Matis,et al.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. , 1995, The Journal of clinical investigation.

[27]  O. Götze,et al.  C3 PROACTIVATOR CONVERTASE AND ITS MODE OF ACTION , 1972, The Journal of experimental medicine.

[28]  D. Tyan,et al.  C1q assay for the detection of complement fixing antibody to HLA antigens. , 2013, Methods in molecular biology.

[29]  B. Lavingia,et al.  Peripheral blood B cells producing donor-specific HLA antibodies in vitro. , 2009, Human immunology.

[30]  G. Einecked,et al.  Banff 07 Classification of Renal Allograft Pathology : Updates and Future Directions , 2008 .

[31]  D. Fearon,et al.  The role of antibody in the activation of the alternative complement pathway , 2005, Springer Seminars in Immunopathology.

[32]  M. Pollack,et al.  Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. , 1992, The Journal of infectious diseases.

[33]  R. Marcén,et al.  Immunoglobulin class and specificity of lymphocytotoxic antibodies after kidney transplantation. , 1988, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.